We also show that UDCA, an FDA approved drug linked to FTD/ALS therapy but whose mechanism of action is unclear [19, 59], stimulates VAPB-PTPIP51 binding and corrects TDP43 linked damage to the VAPB-PTPIP51 interaction and IP3 receptor delivery of Ca2+ to mitochondria. Here, RMDN3 is linked to amyotrophic lateral sclerosis.